Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bolt Biotherapeutics (BOLT) Cash from Operations (2020 - 2025)

Bolt Biotherapeutics (BOLT) has disclosed Cash from Operations for 6 consecutive years, with 7156000.0 as the latest value for Q4 2025.

  • Quarterly Cash from Operations rose 50.41% to 7156000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 39850000.0 through Dec 2025, up 34.98% year-over-year, with the annual reading at 39850000.0 for FY2025, 34.98% up from the prior year.
  • Cash from Operations hit 7156000.0 in Q4 2025 for Bolt Biotherapeutics, up from 9732000.0 in the prior quarter.
  • In the past five years, Cash from Operations ranged from a high of 3986000.0 in Q2 2021 to a low of 24314000.0 in Q1 2022.
  • Historically, Cash from Operations has averaged 15211700.0 across 5 years, with a median of 15627000.0 in 2023.
  • Biggest five-year swings in Cash from Operations: soared 67.5% in 2021 and later crashed 421.5% in 2022.
  • Year by year, Cash from Operations stood at 17794000.0 in 2021, then fell by 0.89% to 17952000.0 in 2022, then rose by 20.54% to 14265000.0 in 2023, then fell by 1.16% to 14430000.0 in 2024, then surged by 50.41% to 7156000.0 in 2025.
  • Business Quant data shows Cash from Operations for BOLT at 7156000.0 in Q4 2025, 9732000.0 in Q3 2025, and 9597000.0 in Q2 2025.